Restricted access

Research article

First published online November 17, 2025

Request permissions

Bictegravir/Emtricitabine/Tenofovir Alafenamide in Pregnant Women Infected with HIV-1: Real-Life Use

Antoine Bachelard https://orcid.org/0000-0002-4682-4916 [email protected], Zélie Julia, […], Florence Damond, Tiphaine Barral, Victoire Pauphilet, Malika Nabil, Lahcene Allal, Yara Wakim, Sylvie Lariven, Aurélie Sinna, Valentine-Marie Ferré, Gilles Peytavin, and Jade Ghosn+10View all authors and affiliations

Volume 42, Issue 2

https://doi.org/10.1177/08892229251398861

View article versions

Abstract
References

Abstract

Bictegravir/Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF) is a convenient, well-tolerated, once-daily, and single-tablet regimen. There are few data on its use during pregnancy. The primary objective was to evaluate the efficacy of BIC/FTC/TAF at delivery, defined as a plasma viral load <50 cp/mL. We conducted a retroprospective, single-center study including pregnant women living with HIV-1 who were on BIC/FTC/TAF. From January 2020 to January 2023, 12 women living with HIV-1 received BIC/FTC/TAF during pregnancy and at delivery. Two were receiving BIC/FTC/TAF at conception and remained on the same combination antiretroviral therapy (cART) throughout the pregnancy, and 10 received BIC/FTC/TAF at least during the third trimester and at delivery. Ten had a plasma viral load <50 cp/mL at delivery. The two who were not suppressed at delivery reported nonadherence to BIC/FTC/TAF, which was not related to treatment side effects. Reported tolerance was good. BIC/FTC/TAF might be a good option during pregnancy and particularly to simplify previous cART but it is necessary to counsel patients to ensure good adherence to this one.

Get full access to this article

View all access and purchase options for this article.

References

1. Grossesse VIH, et al. désir d’enfant, soins de la femme enceinte et prévention de la transmission mère-enfant. recommandations validées par le college nationale du SIDA et des hepatites le. 2024. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2024-05/recommandations_vih_grossesse_22_mai_2024.pdf

2. Department of Health and Human Services, USA. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2021. Available from: https://clinicalinfo.hiv.gov/en/guidelines

3. Tubiana R, Le Chenadec J, Rouzioux C, et al. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: A case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis, 2010; 50(4):585–596;

4. Zash R, Holmes L, Diseko M, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. Presented at: International AIDS Conference; 2020.

5. EMA. Biktarvy public assessment, Gilead Sciences. 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/biktarvy-epar-product-information_en.pdf [Last accessed: May11, 2021].

6. Thimm MA, Livingston A, Ramroop R, et al. Pregnancy outcomes in pregnant women with HIV on Tenofovir Disoproxil Fumarate (TDF) compared to Tenofovir Alafenamide (TAF). J AIDS HIV Treat, 2022; 4(1):6–13.

7. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: A systematic review and meta-analysis. AIDS, 2012; 26(16):2039–2052;

8. Jung BH, Rezk NL, Bridges AS, et al. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr, 2007; 21(10):1095–1104;

9. Mortier E, Froidefond M, Serhal R, et al. Bictegravir use during pregnancy. Infect Dis Now, 2025; 55(6):105093;

10. Zhang H, Hindman JT, Lin L, et al. A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV. AIDS, 2024; 38(1):F1–F9;

11. Powis KM, Pinilla M, McMorrow F, et al.; IMPAACT 2026 Protocol Team. Pharmacokinetics and safety of Bictegravir in Pregnant and postpartum persons With HIV and their infants. J Acquir Immune Defic Syndr, 2025; 98(3):300–307;

12. Rosemary M. Birth. Outcomes Following Bictegravir Use During Pregnancy. In: Conference on Retroviruses and Opportunistic Infections; 2024; Denver, Colorado; Abstract nr 933.

13. Hodgson I, Plummer ML, Konopka SN, et al. A systematic review of individual and contextual factors affecting ART initiation, adherence, and retention for HIV-infected pregnant and postpartum women. PLoS One, 2014; 9(11):e111421;

14. Burke RM, Rickman HM, Pinto C, et al. Reasons for disengagement from antiretroviral care in the era of “Treat All” in low- or middle-income countries: A systematic review. J Int AIDS Soc, 2024; 27(3):e26230;

15. Zheng Y, Hirt D, Delmas S, et al. Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial. Antimicrob Agents Chemother, 2020; 64(10):e00759–e00720;

|

You currently have no access to this content. Visit the access options page to authenticate.